Financial Performance - Revenue for Q1 2025 was $39.371 million, a decrease of 17% compared to $47.620 million in Q1 2024[18] - The net loss for Q1 2025 was $2.847 million, compared to a net income of $6.029 million in Q1 2024, reflecting a significant decline in profitability[18] - Adjusted net loss for the three months ended March 31, 2025, was $1.1 million, compared to an adjusted net income of $1.9 million for the same period in 2024[123] - For the three months ended March 31, 2025, the company generated approximately $39.4 million in revenue, a decline of approximately 17% compared to $47.6 million for the same period in 2024[101] - The company reported a net loss of $2.847 million for Q1 2025, compared to a net income of $6.029 million in Q1 2024[112] Expenses and Costs - Operating expenses increased to $40.960 million in Q1 2025, up from $36.608 million in Q1 2024, primarily due to a rise in selling, general, and administrative expenses[18] - Selling, general and administrative expenses increased by $6.0 million, or 38.2%, for the three months ended March 31, 2025, with selling expenses decreasing to approximately $9.6 million from $11.2 million[126][127] - Cost of service decreased by $2.1 million, or 11.6%, compared to the same period in 2024, with cost of service as a percentage of revenue at 40.5% for 2025 and 37.9% for 2024[125] - The company incurred rent expenses of $1.8 million for medical office suites in Q1 2025, compared to $1.5 million in Q1 2024[76] Cash and Liquidity - Cash and cash equivalents decreased to $5.553 million as of March 31, 2025, down from $8.235 million at the end of 2024[15] - The Company maintains cash balances that may exceed the amount covered by the Federal Deposit Insurance Corporation, with no losses experienced in such accounts[37] - The company is required to maintain minimum liquidity of $3.0 million as of March 31, 2025, increasing to $7.5 million thereafter[147] Assets and Liabilities - Total assets as of March 31, 2025, were $203.260 million, a decrease from $209.996 million at the end of 2024[15] - Total liabilities decreased to $125.927 million as of March 31, 2025, compared to $130.706 million at the end of 2024[15] - As of March 31, 2025, total debt, net was $68.5 million, down from $69.7 million as of December 31, 2024[74] Tax and Regulatory - The effective tax rate for the three months ended March 31, 2025, was approximately 11.4%, significantly lower than the 36.4% rate for the same period in 2024[59] - The effective tax rate for the three months ended March 31, 2025, was 11.4%, compared to 36.4% for the same period in 2024[131] Operational Metrics - The company performed 3,076 cases in Q1 2025, down from 3,746 cases in Q1 2024, representing a case growth decline of 17.9%[104] - Same-center case growth declined by 24.3% in Q1 2025, with revenue per case slightly increasing by 0.5% to $12,777[107] - The number of facilities increased to 32 in Q1 2025 from 27 in Q1 2024, and the total number of procedure rooms rose to 67 from 57[104] Debt and Financing - The Company voluntarily prepaid $10.0 million of the principal balance of term loans under the Credit Agreement on September 29, 2023[69] - The Company entered into a credit agreement on November 7, 2022, with an original aggregate principal amount of term loans of $85.0 million and a revolving loan facility of up to $5.0 million[144] - As of March 31, 2025, the total indebtedness of the company was $73.5 million, including $5.0 million drawn on the revolving credit facility[143] Equity and Compensation - The Company granted 888,301 restricted stock units (RSUs) in Q1 2025, up from 411,456 RSUs in Q1 2024[79] - The Company recorded equity-based compensation expense of $1.2 million for Q1 2025, compared to a reversal of $(6.8) million in Q1 2024[83] Strategic Initiatives - The company has implemented a cost reduction program expected to eliminate approximately $3.0 million in annual overhead costs and contracted expenses[102] - The company is focusing on new product innovation, including a pilot skin tightening procedure as a standalone offering[105] - The company plans to launch expanded consumer financing offerings across all centers by the end of Q2 2025[105] Miscellaneous - There were no changes in internal control over financial reporting that materially affected the company during the quarter ended March 31, 2025[157] - No relevant financial performance or user data was provided in the documents[169] - There are no future outlook or performance guidance details available in the content[170] - No information regarding new products or technology development was found in the documents[171] - There are no mentions of market expansion or acquisitions in the provided content[172] - No new strategies or initiatives were outlined in the documents[172]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 was $39.4 million, a decline of 17.3% from Q1 2024, with adjusted EBITDA at $3.8 million and a margin of 9.5%, down from $7.3 million and 15.4% in the prior year [6][23][24] - Same store revenue decreased approximately 24% year-over-year, consistent with previous trends [7][20] - Average revenue per case was $12,799, slightly higher than the first quarter of 2024 [20][23] Business Line Data and Key Metrics Changes - Cases declined by 17.9% to 3,070, primarily due to lower consumer spending and reduced marketing efforts [20][21] - The percentage of patients using financing for procedures was 44%, down from 50% in the previous quarter [21] Market Data and Key Metrics Changes - The company operates in a challenging macroeconomic environment, impacting consumer spending and case volumes [5][18] - Despite the decline, there was an improvement in lead generation and case performance from February to April 2025 [7][20] Company Strategy and Development Direction - The company is focused on stabilizing performance and laying the foundation for long-term growth through cost discipline, marketing efficiency, and operational rigor [5][6] - Strategic priorities include reallocating marketing spend to effective channels, optimizing sales processes, and introducing new services to meet consumer demand [14][15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation efforts and the potential for future growth, despite current economic pressures [5][19] - The guidance for fiscal 2025 anticipates revenue between $160 million and $170 million, with adjusted EBITDA between $16 million and $18 million, reflecting a cautious outlook due to uncertain consumer behavior [17][25] Other Important Information - The company is monitoring inflationary pressures and consumer sentiment, which could impact discretionary spending on procedures [18] - Cost of service decreased by $2.1 million compared to the prior year, but as a percentage of revenue increased to 40.5% due to fixed costs [21][22] Q&A Session Summary Question: Specific cost savings and sustainability - Management noted significant cost savings from workforce changes, targeting $3 million in savings for the year [28] Question: Potential EBITDA margins and case growth - Management expects EBITDA margins to approach historical levels of around 30% as same store revenue improves [30] Question: Momentum in cases and seasonal patterns - Management confirmed improvements in cases were both seasonal and due to strategic initiatives, with a target for same store sales growth by year-end [31] Question: Underlying assumptions in guidance - Guidance incorporates a range of scenarios, with the low end accounting for further moderation in consumer spending [47][48] Question: Financing options and their impact - Financing options are expected to roll out by the end of Q2, which management believes will help increase case volumes [52][54]

Exhibit 99.1 AirSculpt Technologies Reports First Quarter Fiscal 2025 Results and Full Year Guidance MIAMI BEACH, Fla., May 2, 2025 (GLOBE NEWSWIRE) – AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the first quarter ended March 31, 2025. "We began the year reporting results in line with our expectations, and while we are early in our transformation, I am encouraged by the progress the team has m ...

Core Insights - AirSculpt Technologies, Inc. reported first-quarter results for 2025, indicating a focus on returning to growth through strategic initiatives and cost management [1][2]. Financial Performance - Case volume for Q1 2025 was 3,076, a decline of 17.9% from 3,746 in Q1 2024 [6][22]. - Revenue decreased by 17.3% to $39.4 million from $47.6 million in the same quarter of the previous year [6][17]. - The company reported a net loss of $2.8 million compared to a net income of $6.0 million in Q1 2024 [6][17]. - Adjusted EBITDA was $3.8 million, down from $7.3 million in Q1 2024, with an adjusted EBITDA margin of 9.5% compared to 15.4% [6][22]. Strategic Initiatives - The CEO expressed confidence in the company's transformation efforts and highlighted the early benefits from a new go-to-market strategy, which has improved lead volumes and revenue decline [2]. - The company is focusing on increasing lead generation, consultations, and case conversions through enhanced marketing and sales efforts [2]. - AirSculpt is piloting a standalone skin tightening service, which has garnered increasing interest, positioning the company to capitalize on this opportunity [2]. Liquidity and Cash Flow - As of March 31, 2025, the company had $5.6 million in cash and cash equivalents, down from $8.2 million at the end of 2023 [5][19]. - Operating cash flow for Q1 2025 was $0.9 million, a decrease from $3.4 million in Q1 2024 [5][21]. 2025 Outlook - The company projects full-year 2025 revenue between $160 million and $170 million, with adjusted EBITDA guidance of approximately $16 million to $18 million [4][6].

MIAMI BEACH, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS) an industry leader and provider of premium body contouring procedures, today announced it will report first quarter 2025 financial results before market open on Friday, May 2, 2025, to be followed by a conference call on the same day at 8:00 a.m. Eastern Time. The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference I ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:AirSculpt Technologies, Inc. (AIRS) is a holding company for EBS Intermediate Parent LLC. The Zacks Consensus Estimate for its current year earnings has been revised 121.7% downward over the last 60 days.The Carlyle Group Inc. (CG) is an investment firm. The Zacks Consensus Estimate for its current year earnings has been revised 8.4% downward over the last 60 days.Cars.com Inc. (CARS) provides solutions for the automotive industry. Th ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:AirSculpt Technologies, Inc. (AIRS) is a holding company for EBS Intermediate Parent LLC. The Zacks Consensus Estimate for its current year earnings has been revised 121.7% downward over the last 60 days.Eagle Bancorp, Inc. (EGBN) is the bank holding company for EagleBank. The Zacks Consensus Estimate for its current year earnings has been revised 5.3% downward over the last 60 days.First Foundation Inc. (FFWM) is a banking services, ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Avanos Medical, Inc. (AVNS) is a medical technology company focusing on delivering medical device solutions. The Zacks Consensus Estimate for its current year earnings has been revised 31.8% downward over the last 60 days.AirSculpt Technologies, Inc. (AIRS) is a holding company for EBS Intermediate Parent LLC. The Zacks Consensus Estimate for its current year earnings has been revised 121.7% downward over the last 60 days.Amphastar Ph ...

Financial Data and Key Metrics Changes - For Q4 2024, revenue totaled $39.2 million, a decline of 17.7% from Q4 2023, with case volume down 16.7% year-over-year [13][33] - Adjusted EBITDA was $1.9 million or 4.7% of revenue, compared to $10.1 million or 21.2% of revenue in the same quarter last year [16][38] - For the full year, revenues were $180.4 million, a decline of 7.9% from fiscal 2023, with adjusted EBITDA of $20.7 million and an adjusted EBITDA margin of 11.5% [18][39] Business Line Data and Key Metrics Changes - Same-store revenue declined 22.6% year-over-year in Q4 2024, reflecting challenges in the aesthetics market [13][33] - The percentage of patients using financing for procedures was 50%, down from 53% in previous quarters [34] Market Data and Key Metrics Changes - The company operates in a $11 billion total addressable market in the U.S. [11] - The consumer backdrop remains challenging, impacting sales across the aesthetics space [14] Company Strategy and Development Direction - The company aims to enhance its culture and align on a singular vision while improving its go-to-market strategy to drive consistent revenue growth [20] - Five key priorities include marketing to drive consumer interest, sales to convert leads, new services to tap into demand, customer experience improvements, and technology enhancements [20][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that Q4 2024 was a challenging period but remains confident in the strategy to restore growth and profitability [44] - The company expects Q1 same-store revenue performance to mirror Q4 2024 trends, with sequential improvement anticipated as marketing spend increases [30][42] Other Important Information - The company has paused new center openings to focus on improving same-center performance [29] - A revised credit agreement enhances the company's ability to invest in the business during the transformation [31][41] Q&A Session Summary Question: Can you provide more color on sequential growth expectations? - Management expects to see a similar seasonal trend with sequential improvement in same-store performance year-over-year, anticipating Q2 to be higher than Q1 [51] Question: What are the liquidity improvement actions being taken? - The company drew down on its revolving credit facility to maintain marketing efforts while facing challenges in Q4 results [56] Question: Can you elaborate on the marketing spend versus customer acquisition cost (CAC)? - The elevated CAC was driven by lower case volumes and reduced lead volumes due to decreased marketing spend [62] Question: What is the status of the cost savings program? - The company has executed a $3 million annual savings plan primarily from corporate headcount reductions, with benefits expected to start in Q1 [67] Question: Can you provide specifics on new marketing efforts? - The company is utilizing a combination of paid search and social marketing, with a focus on returns-based approaches and testing new channels like online video [72] Question: What are the plans for new services, particularly skin tightening? - The company plans to pilot skin tightening as a standalone service, capitalizing on consumer interest and trends [76]

Financial Data and Key Metrics Changes - For Q4 2024, revenue totaled $39.2 million, a decline of 17.7% from Q4 2023, with case volume down 16.7% year-over-year [13][33] - Adjusted EBITDA was $1.9 million or 4.7% of revenue, compared to $10.1 million or 21.2% of revenue in the same quarter last year [16][38] - For the full year, revenues were $180.4 million, a decline of 7.9% from fiscal 2023, with adjusted EBITDA of $20.7 million and an adjusted EBITDA margin of 11.5% [18][39] Business Line Data and Key Metrics Changes - Same-store revenue declined 22.6% year-over-year in Q4 2024, reflecting challenges in the aesthetics market [13][33] - The average spend per procedure remained between $12,000 and $13,000, indicating a longer conversion time from leads to cases, increasing from approximately 45 days to closer to 60 days in the second half of 2024 [14][15] Market Data and Key Metrics Changes - The percentage of patients using financing for procedures was 50%, down from 53% in previous quarters, indicating a shift in consumer behavior [34] - The company operates in a $11 billion total addressable market in the U.S., highlighting significant growth potential despite current challenges [11] Company Strategy and Development Direction - The company aims to enhance its culture and align on a singular vision while improving its go-to-market strategy to drive consistent revenue growth [20][29] - Five key priorities include marketing to drive consumer interest, improving sales processes, introducing new services, enhancing customer experience, and leveraging technology [20][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging consumer backdrop affecting sales across the aesthetics space and emphasized the need for internal corrections [14][12] - The company expects Q1 2025 same-store sales performance to mirror Q4 2024 trends, with an anticipated sequential improvement as marketing spend increases [30][42] Other Important Information - The company has paused new center openings to focus on improving same-center performance and has amended its credit agreement to enhance investment flexibility [29][31] - Cash flow from operations for the year was $11.4 million, down from $24 million in fiscal 2023, with gross debt outstanding at $75.8 million [41] Q&A Session Summary Question: Can you provide more color on sequential growth expectations? - Management expects to see a similar seasonal trend with sequential improvement in same-store performance year-over-year, particularly in Q2 [51] Question: What are the liquidity improvement actions being taken? - The company drew down on its revolving credit facility to maintain marketing efforts while facing challenges in Q4 results [56] Question: How should we think about marketing spend versus customer acquisition cost (CAC)? - The elevated CAC was driven by lower case volumes and reduced lead volumes due to decreased marketing spend, but improvements in marketing strategy are expected to lower CAC in the future [62] Question: Can you elaborate on the cost savings program? - The company has executed a $3 million annual savings plan primarily through reductions in corporate headcount not aligned with the current strategy, with benefits expected to start in Q1 [67] Question: What specifics can you share about new marketing efforts? - The company is combining traditional paid search with new initiatives like online video and social marketing, focusing on a returns-based approach to optimize spending [72]